Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PTC Therapeutics, Inc. - Common Stock
(NQ:
PTCT
)
75.96
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PTC Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 19, 2023
Via
Benzinga
NASDAQ:PTCT Shareholder Notice: Investigation over Possible Securities Laws Violations by PTC Therapeutics, Inc.
↗
October 10, 2023
San Diego, CA -- (SBWIRE) -- 10/10/2023 -- PTC Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
↗
October 06, 2023
Via
Benzinga
Expert Ratings for PTC Therapeutics
↗
September 19, 2023
Via
Benzinga
Where PTC Therapeutics Stands With Analysts
↗
August 07, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
October 02, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
October 02, 2023
On Monday, 369 companies set new 52-week lows.
Via
Benzinga
Raymond James Maintains Outperform Rating for PTC Therapeutics: Here's What You Need To Know
↗
August 04, 2023
Via
Benzinga
Earnings Scheduled For August 3, 2023
↗
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
Where PTC Therapeutics Stands With Analysts
↗
July 20, 2023
Via
Benzinga
Dell Technologies To Rally More Than 15%? Here Are 10 Other Analyst Forecasts For Tuesday
↗
September 19, 2023
Raymond James increased the price target for Vital Energy, Inc. (NYSE: VTLE) from $54 to $67. Raymond James analyst John Freeman maintained an Outperform rating. Vital Energy shares rose 0.5% to $54.37...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
↗
September 18, 2023
Via
Benzinga
Morgan Stanley Maintains Equal-Weight Rating for PTC Therapeutics: Here's What You Need To Know
↗
July 11, 2023
Via
Benzinga
What 15 Analyst Ratings Have To Say About PTC Therapeutics
↗
June 30, 2023
Via
Benzinga
Micron Technology To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
↗
September 18, 2023
Piper Sandler cut the price target for IBEX Limited (NASDAQ: IBEX) from $24 to $17. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. IBEX shares rose 0.3% to close at $13.59 on...
Via
Benzinga
US Stock Futures Edge Higher Amid Cautious Optimism; Analyst Says How Fed Packages Sept. Pause Key For Market Direction
↗
September 18, 2023
US stock futures point to a higher opening on Monday after averages closed nearly flat in the week ended Sept. 15.
Via
Benzinga
Topics
Economy
European Authority Gives Thumbs Down To PTC Therapeutics' Duchenne Therapy; Analyst Says It Can Overturn The Challenge
↗
September 15, 2023
Friday morning, the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a negative opinion on the conversion of the conditional marketing authorization to full...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
September 15, 2023
Via
Benzinga
Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
September 15, 2023
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results.
Via
Benzinga
Nasdaq Down Over 1%; US Industrial Output Rises In August
↗
September 15, 2023
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% points on Friday. The Dow traded down 0.52% to 34,727.05 while the NASDAQ fell 1.31% to 13,743.78. The...
Via
Benzinga
Topics
Stocks
PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday
↗
September 15, 2023
U.S. stocks traded higher, with the Dow Jones falling around 180 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Topics
Stocks
Stocks That Hit 52-Week Lows On Friday
↗
September 15, 2023
Friday's session saw 169 companies set new 52-week lows.
Via
Benzinga
Dow Dips 100 Points; US Export Prices Rise 1.3% In August
↗
September 15, 2023
U.S. stocks traded lower this morning, with the Dow Jones falling around 100 points on Friday. Following the market opening Friday, the Dow traded down 0.31% to 34,799.50 while the NASDAQ fell 1.09% to...
Via
Benzinga
Topics
Stocks
PTC Therapeutics Crashes 29% After European Regulators Reject Its Muscular Dystrophy Drug
↗
September 15, 2023
The company is working on a treatment for Duchenne muscular dystrophy.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
↗
September 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
September 15, 2023
Via
Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
↗
August 25, 2023
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy.
Via
InvestorPlace
PTC Therapeutics' Seizure Study Fails To Meet Primary Goal, Analyst Says Minimal Impact On Investment Thesis
↗
June 30, 2023
PTC Therapeutics Inc (NASDAQ: PTCT) said its MIT-E trial of vatiquinone for mitochondrial disease-associated seizures (MDAS) failed to achieve its primary endpoint of
Via
Benzinga
PTC Therapeutics Says Interim Data For Huntington's Disease Candidate Shows Promise In Mid-Stage Study
↗
June 21, 2023
PTC Therapeutics Inc (NASDAQ: PTCT) shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in
Via
Benzinga
3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs
↗
May 31, 2023
Small-cap stocks can be risky, and all three of these companies are facing adversity. But they could be home run investments.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.